research use only
Cat.No.S7099
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR |
|---|---|
| Other ATPase Inhibitors | Thapsigargin Brefeldin A (BFA chemical) CB-5083 Sodium orthovanadate Golgicide A BTB06584 Ginsenoside Rb1 CDN1163 Periplocin Rhodamine 123 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 39 mg/mL
(133.41 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 292.33 | Formula | C18H16N2O2 |
Storage (From the date of receipt) | 3 years -20°C(in the dark) powder |
|---|---|---|---|---|---|
| CAS No. | 856925-71-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | (S)-(-)-Blebbistatin | Smiles | CC1=CC2=C(C=C1)N=C3C(C2=O)(CCN3C4=CC=CC=C4)O | ||
| Targets/IC50/Ki |
non-muscle myosin II ATPases
(Cell-free assay) 0.5 μM-5 μM
|
|---|---|
| In vitro |
(-)-Blebbistatin, inhibits cytokinesis, alters the smooth movement of fish keratocytes and inhibits the spontaneous blebbing of a cell line lacking filamin. This compound is shown to inhibit the enzymatic activities of HMM fragments of nonmuscle myosin IIA, nonmuscle myosin IIB and of rabbit skeletal muscle myosin S1, but not smooth muscle myosin This chemical rapidly and reversibly inhibits Mg-ATPase activity and in vitro motility of non-muscle myosin IIA and IIB for several species, while poorly inhibiting smooth muscle myosin (IC50 = 80 μM). It potently inhibits Dictyostelium myosin II, but poorly inhibits Acanthamoeba myosin II. This compound does not inhibit representative myosin superfamily members from classes I, V, and X. It does not compete with nucleotide binding to the skeletal muscle myosin subfragment-1. The inhibitor preferentially binds to the ATPase intermediate with ADP and phosphate bound at the active site, and it slows down phosphate release. This chemical interferes neither with binding of myosin to actin nor with ATP-induced actomyosin dissociation. Instead, it blocks the myosin heads in a products complex with low actin affinity. |
| Kinase Assay |
Actin-activated MgATPase assay
|
|
Actin-activated MgATPase activity is measured using an NADH-coupled assay in a Beckman DU 640 spectrophotometer. (-)-Blebbistatin [a racemic mixture of the (+) and (-) enantiomers] is added from stocks dissolved in DMSO and the DMSO concentration is maintained at a constant concentration of 5% in all samples.
|
|
| In vivo |
(-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | talin 1 / vinculin / paxillin paxillin / pY31 paxillin / pY397FAK / FAK PY epitopes / vinculin / paxillin |
|
20308429 |
| Growth inhibition assay | Cell viability Cell death |
|
26733241 |
| Glycerol/urea gel electrophoresis | RLC phosphorylation RLC phosphorylation RLC phosphorylation |
|
18701651 |
| DIC image | Traction force of a palladin KD (Palld4) cell |
|
27353427 |
| Immunofluorescence | GCs morphology actin / NMIIA / tubulin VE-cadherin / F-actin PY epitopes / actin PY epitopes / paxillin talin 1 / FAK / β1 integrin / zyxin / vinculin / α-actinin / paxillin |
|
25598228 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.